Healing Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies With Metformin-Based Eye Drops Formulations For Macular Degeneration Treatment

Curative Biotechnology, Inc. appoints Cary Sucoff to the Board of Directors

Healing Biotechnology, Inc.

The appointment of the Independent Director adds to the financial responsibilities of the Board

Boca Raton, FL, May 12, 2022 (GLOBE NEWSWIRE) – Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or “Company”), a developing biomedical company focused on new treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its board of directors as an independent director. With over 35 years of experience in the legal and securities sector, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of directors or consultant of six healthcare and biotech companies. Mr. Sucoff is an expert in legal, compliance, business strategy and capital markets and has chaired or participated in audit, clearing, nomination / governance and special committees.

About Cary Sucoff

Since 2011, Sucoff has owned and operated Equity Source Partners LLC, a consulting and consulting firm. Currently, Sucoff sits on the following boards:

Contrafect Corp. – engaged in Phase 3 development of new treatments for infectious diseases using proprietary antibody and lysine technology (Audit; Nom / Gov; Pricing).

Holding IMAC – provides motor and orthopedic therapies and minimally invasive procedures performed through regenerative and rehabilitative medical treatments provided in clinics and private facilities within Walmart stores. (Audit; Nom / Gov; Comp).

Galimedix TherapeuticsInc. – Technology licensed from Tel Aviv University for potentially revolutionary treatments for glaucoma and age-related dry macular degeneration (Audit; Nom / Gov).

Technologies of the first waveInc. – new and innovative medical device technologies focused on anesthesia and ventilator technology (M&A).

In addition, Mr. Sucoff is currently a consultant for:

Sapience Therapeutics, Inc. – a Phase 1/2 Biotech company focused on Glioblastoma.

LB Pharmaceuticals – a New York-based biotech company developing a new Phase 2 drug for the treatment of schizophrenia.

Kinetic power systems – an energy developer and manufacturer of long-life flywheel energy storage systems or mechanical batteries.

Mr. Sucoff, a former New York City attorney, is the Past President of New England Law / Boston (Boston, Ma.) And is the senior member of its Board of Trustees, where he served for over 30 years. He has been Chairman of the Endowment Committee for over 10 years and sits on the Finance Committee. Mr. Sucoff holds a BA from SUNY Binghamton (1974) and a JD from the New England School of Law (1977) where he was editor-in-chief of Law Review and a graduate of Magna Cum Laude. Mr. Sucoff has been a member of the New York State Bar (now retired) since 1978.

Press releases and future updates of curative biotechnology

Interested investors and shareholders can be notified of future press releases and industry updates by email ir@curativebiotech.com

Information on Curative Biotechnology, Inc. http://curativebiotech.com

Curative Biotechnology, Inc. (Curative Biotech) is a developing biomedical company focused on novel therapies for rare diseases. The company is focused on the identification, acquisition and development of disease-modifying therapeutic drug candidates with a focus on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious diseases, neuro oncology and degenerative diseases of the eye. The company’s pipeline includes IMT504, CURB906, and metformin reformulation. IMT504 is a new immune therapy for the treatment of rabies and an adjuvant for vaccines. CURB906 is a fully humanized CD56 monoclonal antibody that delivers a conjugated cytotoxic drug directly to the tumor site to kill the tumor by inhibiting tumor growth and tumor migration. The reformulation of metformin is aimed at the treatment of intermediate and advanced age-related macular degeneration disease (AMD).

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenue. Although the forward-looking statements contained in this release reflect the good faith judgment of management, the forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those discussed in these forward-looking statements, including including but not limited to our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow and general economic conditions. Readers are encouraged to carefully review and consider the various disclosures we provide in our reports filed from time to time with OTC Markets which attempt to warn interested parties of the risks and factors that may affect our business, financial condition, results of operations and liquidity flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results could vary materially from those expected or anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We undertake no obligation to update any forward-looking statements to reflect any event or circumstance that may occur after the date of this release.


Steve Chizzik
Investor Relations
Healing Biotechnology (CUBT)

Leave a Comment

Your email address will not be published.